PMID- 28552950
OWN - NLM
STAT- MEDLINE
DCOM- 20170918
LR  - 20220408
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 5
DP  - 2017
TI  - Genomic profile of human meningioma cell lines.
PG  - e0178322
LID - 10.1371/journal.pone.0178322 [doi]
LID - e0178322
AB  - Meningiomas, derived from arachnoid cap cells, are the most common intracranial 
      tumor. High-grade meningiomas, as well as those located at the skull base or near 
      venous sinuses, frequently recur and are challenging to manage. Next-generation 
      sequencing is identifying novel pharmacologic targets in meningiomas to 
      complement surgery and radiation. However, due to the lack of in vitro models, 
      the importance and implications of these genetic variants in meningioma 
      pathogenesis and therapy remain unclear. We performed whole exome sequencing to 
      assess single nucleotide variants and somatic copy number variants in four human 
      meningioma cell lines, including two benign lines (HBL-52 and Ben-Men-1) and two 
      malignant lines (IOMM-Lee and CH157-MN). The two malignant cell lines harbored an 
      elevated rate of mutations and copy number alterations compared to the benign 
      lines, consistent with the genetic profiles of high-grade meningiomas. In 
      addition, these cell lines also harbored known meningioma driver mutations in 
      neurofibromin 2 (NF2) and TNF receptor-associated factor 7 (TRAF7). These 
      findings demonstrate the relevance of meningioma cell lines as a model system, 
      especially as tools to investigate the signaling pathways of, and subsequent 
      resistance to, therapeutics currently in clinical trials.
FAU - Mei, Yu
AU  - Mei Y
AUID- ORCID: 0000-0001-9865-1765
AD  - Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham 
      and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United 
      States of America.
FAU - Bi, Wenya Linda
AU  - Bi WL
AD  - Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham 
      and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United 
      States of America.
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts, United States of America.
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of 
      America.
FAU - Greenwald, Noah F
AU  - Greenwald NF
AD  - Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham 
      and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United 
      States of America.
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts, United States of America.
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of 
      America.
FAU - Agar, Nathalie Y
AU  - Agar NY
AD  - Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham 
      and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United 
      States of America.
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts, United States of America.
FAU - Beroukhim, Rameen
AU  - Beroukhim R
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts, United States of America.
AD  - Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of 
      America.
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts, United States of America.
FAU - Dunn, Gavin P
AU  - Dunn GP
AD  - Department of Neurosurgery, Pathology, and Immunology, Center for Human 
      Immunology and Immunotherapy Programs, Washington University School of Medicine, 
      St. Louis, Missouri, United States of America.
FAU - Dunn, Ian F
AU  - Dunn IF
AD  - Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham 
      and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United 
      States of America.
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 
      Massachusetts, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20170526
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Cell Line, Tumor
MH  - DNA Copy Number Variations
MH  - *Genomics
MH  - Humans
MH  - Meningeal Neoplasms/*genetics/pathology
MH  - Meningioma/*genetics/pathology
MH  - Mutation
PMC - PMC5446134
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/05/30 06:00
MHDA- 2017/09/19 06:00
PMCR- 2017/05/26
CRDT- 2017/05/30 06:00
PHST- 2016/12/23 00:00 [received]
PHST- 2017/03/30 00:00 [accepted]
PHST- 2017/05/30 06:00 [entrez]
PHST- 2017/05/30 06:00 [pubmed]
PHST- 2017/09/19 06:00 [medline]
PHST- 2017/05/26 00:00 [pmc-release]
AID - PONE-D-16-50838 [pii]
AID - 10.1371/journal.pone.0178322 [doi]
PST - epublish
SO  - PLoS One. 2017 May 26;12(5):e0178322. doi: 10.1371/journal.pone.0178322. 
      eCollection 2017.